Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2012

PharmaEngine Nabs Rights to Nanoparticle Radiotherapy Booster

  • Taiwan’s PharmaEngine is paying French firm Nanobiotix $1 million up front for exclusive Asia-Pacific license to the latter’s lead radiotherapy enhancer NBTXR3, which is currently being evaluated in a Phase I trial in patients with soft-tissue sarcoma. The deal gives PharmaEngine exclusive rights to develop NBTXR3 in Australia, China, India, Japan, Korea, Taiwan, and other Asia-Pacific territories. Nanobiotix could receive up to $56 million dependent on reaching specified development, regulatory, and sales milestones, plus sales royalties. The plan is to develop NBTXR3 as a medical device, rather than a drug, to allow faster development and progress through regulatory stages.

    NBTXR3 is a nanoparticle formulation of hafnium oxide crystals, used to enhance the efficacy of radiotherapy. The product has been classified in the EU as a class III medical device. Nanobiotix is a nanomedicine firm developing a pipeline of NanoXray products designed to boost the effects of radiotherapy by effectively increasing the effects of a given dose of radiotherapy on the tumor tissue, without impacting on healthy tissue. Lead product NBTXR3 is designed for intratumoral administration, but Nanobiotix is also developing hafnium oxide-based nanoparticles suitable for administration by other routes including intravenous injection or deposition onto a tumor.

    The firm is separately exploiting its nanoparticle expertise to develop magnetic nanoMag particles for the treatment and diagnosis of cancer, and a nanoPDT photodynamic therapy for cancer therapy.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »